Coherence Neuro Raises $45M for Cancer Neurotechnology

A follow-up appointment can only use the evidence that reaches it. Coherence Neuro is building toward a cancer-care system that could give clinical teams a continuing electrical record from inside the body, extending the information available between visits. That ambition puts a demanding clinical assignment inside the company's neurotechnology business: turn a measurement into something useful enough to guide an intervention.

The San Francisco and Cambridge, UK, company announced a $45M Series A on October 21, 2026, co-led by Founders Fund and The OpenAI Startup Fund. Co-founders Ben Woodington, CEO, and Elise Jenkins, CTO, are developing technology that combines sensing with stimulation, beginning with brain cancer.

The financing supports the transition toward longer-term human studies and the engineering around them. Coherence's existing human research concerns a short-duration surgical device; its proposed chronic system remains under development. For investors and operators following medical AI, the company illustrates how the value of a model can depend on the hardware, clinical workflow and evidence program that supply its inputs.

What Coherence Neuro's Series A will support

Coherence names Lux Capital, 8VC, Timeless, Olive Capital and Ahren among the new institutional participants, with earlier investors including Blackbird and Topology returning. The company plans a chronic glioblastoma study, further preclinical work and team expansion. It also says it is seeking FDA Breakthrough Device designation, a prospective regulatory milestone that should be read as an application goal.

The immediate operating challenge is unusually integrated. A company pursuing an implant has to make decisions about what information to collect, how to collect it consistently and how a clinician should use the result. A change in one part of that chain can alter the requirements elsewhere. Better sensing can create a more demanding data problem, while a more sophisticated model still needs dependable measurements.

That gives the round a purpose beyond expanding a software team. Financing can support the people and development cycles required to bring electronics, biology and clinical practice into the same program. The commercial significance lies in how well those disciplines fit together over time. Coherence has not disclosed a valuation or a verified comprehensive lifetime funding total in the sources reviewed for this article, so neither figure is part of the financing account here.

CIPHER and SOMA represent different clinical assignments

Coherence's June 23 clinical announcement described first-in-human use of CIPHER at Royal Melbourne Hospital, led by neurosurgeon Andrew Morokoff. The study evaluates safety, basic performance and handling during short-duration use in brain tumor surgery. That scope matters when interpreting what the company has already accomplished.

SOMA is the longer-term system Coherence is developing around an implant, a wearable and supporting software. Its product page explicitly identifies the devices as investigational and says they are not approved by the FDA, TGA or other regulatory bodies. The design ambition is continuous monitoring and responsive stimulation; a demonstrated improvement in patient outcomes would require its own clinical evidence.

Moving beyond the operating room changes the product assignment. During surgery, a specialist team can observe the equipment in a controlled setting. A chronic system must be designed around a patient who leaves that setting, with clinical staff responsible for interpreting information over a longer period. The engineering and human-factors questions therefore belong inside the treatment concept from the beginning. A successful recording is valuable research, and the program still has to establish what continuing recordings should mean for care.

Cancer bioelectronics has a precedent and a distinct development path

Electrical treatment already has a place in oncology. The FDA's Optune approval record documents a tumor-treating-fields device for defined glioblastoma indications. That provides regulatory context for readers encountering electrical approaches to cancer, while Coherence's proposed implant and sensing architecture require evaluation on their own terms.

For a buyer or clinical partner, the useful comparison concerns the work each system asks people to perform. An implanted sensing-and-stimulation approach raises questions about placement, data interpretation, follow-up and device support. Those questions can shape adoption alongside scientific performance. A clinician needs a reason to trust the information and a workable way to incorporate it into care.

The resulting business is connected to the practical organization of medicine. Evidence generation, specialist training and product support can affect how a technology travels from a research center to a wider clinical setting. Coherence has not established commercial adoption or comparative outcomes in the sources reviewed here. At this stage, its relevance to the market comes from the development program it is financing and the clinical relationships needed to carry that program forward, rather than a disclosed sales or customer-growth figure.

The team being built around the signal

Woodington and Jenkins met through research at the University of Cambridge. Blackbird's company profile corroborates their backgrounds in bioelectronics and the founding relationship. The company's current leadership page identifies their CEO and CTO roles, giving the financing a clear pair of operating owners.

Coherence's open roles show how broad the next assignment is. Implant electronics, clinical science, test development and surgical human factors appear alongside one another. Those functions sit at different points in the same responsibility: build a device, understand what it records, establish how it should be used and make that use reproducible.

For founders building medical AI, this is a useful view of where a data advantage might come from. Access to a new signal carries obligations around how the signal is obtained and whether it supports a decision. The hardware team, clinical team and researchers all influence the meaning of the resulting dataset. Coherence's next study program will bring those responsibilities into a longer relationship with the patient, where the information arriving at a follow-up appointment has to remain connected to the device and the clinical work that produced it.